Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Plain-language summary

This study provided long-term follow-up of patients who received CLBR001 CAR-T cell therapy (and SWI019). Patients who received at least one CLBR001 cell dose and either completed or discontinued the core treatment protocol were eligible. The study was conducted in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Calibr, a division of Scripps Research

Intervention

CLBR001 and SWI019

Start date

1/21/2021

Estimated completion

10/6/2025

Countries

United States

Related genes

Locations

• Duarte, United States
• San Diego, United States
• Chicago, United States
• Minneapolis, United States
• New York, United States
• Winston-Salem, United States
• Nashville, United States
• San Antonio, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable.
* Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

* There are no specific exclusion criteria for this study